Renal Impairment in Multiple Myeloma

In this third issue, we will be focusing on the impact of novel agents on myeloma-associated renal impairment. Subsequent issues will address the incorporation of best practices for managing treatment-related toxicities, potential economic implications of novel agents used to treat myeloma-related bone complications, and value-based benefit design considerations for the disease.